AR123441A2 - Compuesto de pirazol - Google Patents

Compuesto de pirazol

Info

Publication number
AR123441A2
AR123441A2 ARP210102479A ARP210102479A AR123441A2 AR 123441 A2 AR123441 A2 AR 123441A2 AR P210102479 A ARP210102479 A AR P210102479A AR P210102479 A ARP210102479 A AR P210102479A AR 123441 A2 AR123441 A2 AR 123441A2
Authority
AR
Argentina
Prior art keywords
group
saturated heterocycle
alkyl
membered
represented
Prior art date
Application number
ARP210102479A
Other languages
English (en)
Inventor
Tomoya Miura
Yosuke Ogoshi
Kazuhito Ueyama
Dai Motoda
Toshihiko Iwayama
Koichi Suzawa
Hironobu Nagamori
Hiroshi Ueno
Akihiko Takahashi
Kazuyuki Sugimoto
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR123441A2 publication Critical patent/AR123441A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto o una de sus sales farmacéuticamente aceptables representado por la fórmula general [1], caracterizado porque Anillo Cy es (1) arilo C₆₋₁₀, (2) cicloalquilo C₃₋₈ o (3) cicloalquenilo C₃₋₈, n1 es 0, 1, 2, 3, ó 4, R¹ᵃ está representado (1) un átomo de halógeno, (2) hidroxi, (3) carboxi, (4) un grupo alquilo C₁₋₆, (5) un grupo alquenilo C₂₋₈, (6) un grupo alquinilo C₂₋₈, (7) un grupo alcoxi C₁₋₆, (8) un grupo cicloalquilo C₃₋₆, (9) un grupo haloalquilo C₁₋₆, (10) un grupo hidroxialquilo C₁₋₆, (11) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (12) un grupo haloalcoxi C₁₋₆alquilo C₁₋₆ (13) un grupo alquil C₁₋₆sulfonilalquilo C₁₋₆, (14) un grupo haloalquil C₁₋₆sulfonilalquilo C₁₋₆, (15) un grupo halodialquil C₁₋₆aminoalquilo C₁₋₆, (16) un grupo cicloalquil C₃₋₆alquinilo C₂₋₆, (17) un grupo haloalcoxi C₁₋₆, (18) un grupo carboxialcoxi C₁₋₆, (19) un grupo alquil C₁₋₆sulfanilo, (20) un grupo alquilsulfonilo C₁₋₆, (21) un grupo haloalquilsulfonilo C₁₋₆, (22) un grupo alquil C₁₋₈carbonilo, (23) un grupo alquil C₁₋₆oxicarbonilo, (24) un grupo representado por la fórmula [2], donde R⁵ es (a) un átomo de hidrógeno o (b) un grupo alquilo C₁₋₆, y R⁶ es (a) un grupo alquilo C₁₋₆ o (b) un grupo haloalquilo C₁₋₆, (25) un grupo alquilo C₆₋₁₀ de heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), o (26) un grupo oxialquilo C₁₋₆ de un heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), con la condición de que cuando n1 es 2, 3, ó 4, R¹ᵃ puede ser igual o diferente, R²ᵃ es (1) un grupo hidroxialquilo C₁₋₈, (2) un grupo cicloalquilo C₃₋₈alquilo C₁₋₆, (3) un grupo aril C₆₋₁₀, alquilo C₁₋₆, (4) un grupo alquilo C₆₋₁₀ de heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), (5) un grupo cicloalquilo C₃₋₈, (6) un grupo haloalquilo C₁₋₆, (7) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (8) un grupo halocicloalquilo C₃₋₈, (9) un grupo arilo C₆₋₁₀ (el grupo arilo C₆₋₁₀ está opcionalmente sustituido con 1 a 4 sustituyentes seleccionados de (a) un átomo de halógeno, (b) hidroxi, (c) un grupo alquilo C₁₋₆, (d) un grupo alquenilo C₂₋₈, (e) un grupo alquinilo C₂₋₆, (f) un grupo alcoxi C₁₋₆, (g) un grupo haloalquilo C₁₋₆, (h) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (i) un grupo haloalcoxi C₁₋₆, (j) un grupo hidroxialcoxi C₁₋₆, (k) un grupo alcoxi C₁₋₆alcoxi C₁₋₆, (l) un grupo carboxialcoxi C₁₋₆, (m) un grupo aril C₁₋₆alcoxi C₁₋₆, (n) un grupo alquil C₁₋₆sulfanilalcoxi C₁₋₆, (o) un grupo alquil C₁₋₆sulfonilalcoxi C₁₋₆, (p) un grupo aril C₆₋₁₀alcoxi C₁₋₆alcoxi C₁₋₆, (q) un grupo alcoxi C₁₋₆ del heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, y está opcionalmente sustituido con 1 a 2 grupos alquilo C₁₋₆), (r) un grupo heterociclo oxi saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, (s) un grupo cicloalquil C₃₋₈oxi, (t) un grupo alcoxi C₁₋₆carboniloxi, y (u) un grupo alquilsulfonilo C₁₋₆), o (10) un grupo heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, y está opcionalmente sustituido con 1 a 4 grupos alquilo C₁₋₆), Anillo Cyᵃ es un grupo seleccionado de (1) un grupo representado por la fórmula [3], donde m2 es 1, 2 ó 3, m3 es 1, 2 ó 3, n3 es 1 ó 2, (2) un grupo representado por la fórmula [4], donde m4 es 0, 1, 2 ó 3, m5 es 0, 1 ó 2, siempre que la suma de m4 y m5 sea 1 o más, (3) un grupo representado por la fórmula [5], donde m4 es 0, 1, 2 ó 3, m5 es 0, 1 ó 2, siempre que la suma de m4 y m5 sea 1 o más, (4) un grupo representado por la fórmula [6], donde m6 es 0, 1 ó 2, m7 es 0, 1 ó 2, siempre que la suma de m6 y m7 es 1 o más, (5) un grupo representado por la fórmula [7], donde m6 es 0, 1 ó 2, m7 es 0, 1 ó 2, siempre que la suma de m6 y m7 es 1 o más, (6) un grupo representado por la fórmula [7], donde m8 es 1 ó 2, m9 es 1 ó 2, y (7) un grupo representado por la fórmula [9], donde m8 es 1 ó 2, m9 es 1 ó 2, n2 es 0, 1, 2, 3, ó 4, R³ᵃ es (1) hidroxi, (2) un grupo alquilo C₁₋₆ o (3) un grupo hidroxialquilo C₁₋₆, con la condición de que cuando n2 sea 2, 3, ó 4, R³ᵃ puede ser igual o diferente, R³ᵇ es (1) hidroxi, (2) un grupo alquilo C₁₋₆ (que puede formar un grupo cicloalquilo C₃₋₆ junto con el carbono al que está unido y el carbono adyacente a este) o (3) un grupo hidroxialquilo C₁₋₆, o (4) cuando dos R³ᵇ se unen al mismo carbono, forman un grupo cicloalquilo C₃₋₆ junto con el carbono al que están unidos, siempre que cuando n2 sea 2, 3 ó 4, cada R³ᵇ puede ser igual o diferente, y R⁴ᵇ es (1) un átomo de hidrógeno, (2) un grupo alquilo C₁₋₆, (3) un grupo carboxialquilo C₁₋₆, (4) un grupo haloalquilo C₁₋₆ o (5) un grupo alcoxi C₁₋₆alquilo C₁₋₆.
ARP210102479A 2011-08-31 2021-09-06 Compuesto de pirazol AR123441A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011188121 2011-08-31

Publications (1)

Publication Number Publication Date
AR123441A2 true AR123441A2 (es) 2022-11-30

Family

ID=47756400

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120103173A AR087701A1 (es) 2011-08-31 2012-08-28 Derivados de pirazol con actividad inhibidora de sglt1
ARP210102479A AR123441A2 (es) 2011-08-31 2021-09-06 Compuesto de pirazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120103173A AR087701A1 (es) 2011-08-31 2012-08-28 Derivados de pirazol con actividad inhibidora de sglt1

Country Status (26)

Country Link
US (5) US8846746B2 (es)
EP (3) EP2784074A4 (es)
JP (5) JP6091811B2 (es)
KR (1) KR101989203B1 (es)
CN (1) CN103917535B (es)
AR (2) AR087701A1 (es)
AU (1) AU2012302723B2 (es)
BR (1) BR112014004651B1 (es)
CA (1) CA2845127C (es)
CL (1) CL2014000490A1 (es)
CO (1) CO6890098A2 (es)
CY (1) CY1121631T1 (es)
DK (1) DK3199533T3 (es)
HK (1) HK1202290A1 (es)
IL (1) IL230763A (es)
MX (1) MX359825B (es)
MY (1) MY172422A (es)
PE (1) PE20142343A1 (es)
PL (1) PL3199533T3 (es)
RS (1) RS58870B1 (es)
RU (1) RU2617678C2 (es)
SG (1) SG11201400244YA (es)
SI (1) SI3199533T1 (es)
TW (1) TWI549949B (es)
WO (1) WO2013031922A1 (es)
ZA (1) ZA201401071B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
WO2013168671A1 (ja) 2012-05-07 2013-11-14 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
CA2891644A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
JP5807767B2 (ja) * 2013-02-04 2015-11-10 大正製薬株式会社 便秘症の予防又は治療薬
JP6309080B2 (ja) 2013-05-08 2018-04-18 ザ ユニバーシティ オブ ヒューストン システム がん治療のためのｅｇｆｒ−ｓｇｌｔ１相互作用の標的化
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
WO2018029104A1 (de) 2016-08-11 2018-02-15 Bayer Cropscience Aktiengesellschaft Substituierte pyrazolinylderivate, verfahren zu deren herstellung und ihre verwendung als herbizide und/oder pflanzenwachstumsregulatoren
MX2019001813A (es) 2016-08-15 2019-05-20 Bayer Cropscience Ag Procedimiento para la preparacion de pyrazoles de 3-amino-1-(2,6-disustituido-fenilo).
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CA3151909A1 (en) 2019-09-04 2021-03-11 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3152939A1 (en) * 2019-09-04 2021-03-11 Japan Tobacco Inc. Chronic kidney disease treatment or prevention method
CN115209919A (zh) * 2020-03-19 2022-10-18 日本烟草产业株式会社 慢性心衰的治疗或预防方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2383555C (en) * 1999-08-12 2009-02-17 Paolo Pevarello 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7375087B2 (en) * 2002-08-08 2008-05-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AU2005308575A1 (en) 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
EP1951678A1 (en) 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
US20070117858A1 (en) 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
JP2010505957A (ja) * 2006-10-10 2010-02-25 アムゲン インコーポレイティッド 糖尿病に対して使用されるｎ−アリールピラゾール化合物
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010222298A (ja) * 2009-03-24 2010-10-07 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
EP2594555B1 (en) 2010-07-02 2018-03-07 ASKA Pharmaceutical Co., Ltd. HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Also Published As

Publication number Publication date
JP2020125348A (ja) 2020-08-20
CA2845127A1 (en) 2013-03-07
US20180346449A1 (en) 2018-12-06
EP3199533A1 (en) 2017-08-02
RU2014112048A (ru) 2015-10-10
EP2784074A4 (en) 2015-06-03
TW201321372A (zh) 2013-06-01
EP3524599A1 (en) 2019-08-14
EP2784074A1 (en) 2014-10-01
US20150183763A1 (en) 2015-07-02
NZ620977A (en) 2016-02-26
US8846746B2 (en) 2014-09-30
BR112014004651A2 (pt) 2017-03-28
CL2014000490A1 (es) 2014-08-22
JP2018115216A (ja) 2018-07-26
JP2013063968A (ja) 2013-04-11
PE20142343A1 (es) 2015-01-29
DK3199533T3 (da) 2019-05-20
MX359825B (es) 2018-10-10
EP3199533B1 (en) 2019-02-27
US20200317644A1 (en) 2020-10-08
RS58870B1 (sr) 2019-08-30
US20130085132A1 (en) 2013-04-04
ZA201401071B (en) 2016-10-26
KR101989203B1 (ko) 2019-06-13
CY1121631T1 (el) 2020-07-31
CA2845127C (en) 2020-03-10
CO6890098A2 (es) 2014-03-10
RU2617678C2 (ru) 2017-04-26
JP2023087032A (ja) 2023-06-22
AU2012302723B2 (en) 2016-08-11
TWI549949B (zh) 2016-09-21
WO2013031922A1 (ja) 2013-03-07
MX2014002552A (es) 2014-04-25
AR087701A1 (es) 2014-04-09
IL230763A0 (en) 2014-03-31
IL230763A (en) 2016-10-31
US20230348438A1 (en) 2023-11-02
HK1202290A1 (en) 2015-09-25
JP6091811B2 (ja) 2017-03-08
CN103917535A (zh) 2014-07-09
SI3199533T1 (sl) 2019-06-28
BR112014004651B1 (pt) 2021-08-31
PL3199533T3 (pl) 2019-09-30
SG11201400244YA (en) 2014-10-30
KR20140062048A (ko) 2014-05-22
MY172422A (en) 2019-11-25
CN103917535B (zh) 2015-06-24
JP2017082005A (ja) 2017-05-18
AU2012302723A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
AR123441A2 (es) Compuesto de pirazol
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
TWD195351S (zh) Transformer (2)
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
BR112017006093A2 (pt) moduladores alostéricos negativos de n-alquilaril-5-oxiaril-octa-hidro-ciclopenta[c] pirrol de nr2b
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
RS54730B1 (sr) Inhibitori beta sekretaze
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
DOP2007000014A (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
CR20160198A (es) Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
BR112015028760A2 (pt) compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
UY36574A (es) Inhibidores de bromodominios
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
MY193239A (en) Novel b-lactamase inhibitors